Chordate Medical Holding AB (OSTO:CMH) Accounts Payable: kr1.40 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:CMH Chordate Medical Holding AB OSTO:CMH
46 GF Score
Price kr0.16
View Full Analysis

What is Chordate Medical Holding AB Accounts Payable?

Chordate Medical Holding AB OSTO:CMH -60.40% 46 Accounts Payable is kr1.40 Mil as of Jun. 2025. GuruFocus rates OSTO:CMH with a GF Score™ of 46/100.

Chordate Medical Holding AB's Accounts Payable for the quarter that ended in Jun. 2025 was kr1.40 Mil.

Chordate Medical Holding AB's quarterly Accounts Payable increased from Dec. 2024 (kr2.07 Mil) to Mar. 2025 (kr2.14 Mil) but then declined from Mar. 2025 (kr2.14 Mil) to Jun. 2025 (kr1.40 Mil).

Chordate Medical Holding AB's annual Accounts Payable declined from Dec. 2022 (kr3.51 Mil) to Dec. 2023 (kr2.88 Mil) and declined from Dec. 2023 (kr2.88 Mil) to Dec. 2024 (kr2.07 Mil).

Chordate Medical Holding AB Accounts Payable Related Terms

Chordate Medical Holding AB Accounts Payable Historical Data

* Premium members only.

The historical data trend for Chordate Medical Holding AB's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordate Medical Holding AB Accounts Payable Chart

Chordate Medical Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.95 2.05 3.51 2.88 2.07

Chordate Medical Holding AB Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.50 1.12 2.07 2.14 1.40
OSTO:CMH
46GF Score
Chordate Medical Holding AB OSTO:CMH
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordate Medical Holding AB Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of kr1.40 Mil mean?
Chordate Medical Holding AB (OSTO:CMH) has a Accounts Payable of kr1.40 Mil as of Jun. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Chordate Medical Holding AB and its competitors.
Is Chordate Medical Holding AB's Accounts Payable too high?
Chordate Medical Holding AB's current Accounts Payable is kr1.40 Mil. Overall, Chordate Medical Holding AB has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Chordate Medical Holding AB's Accounts Payable compare to ABT and SYK?
Chordate Medical Holding AB's Accounts Payable of kr1.40 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Devices & Instruments company?
A good Accounts Payable depends on the Medical Devices & Instruments industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Chordate Medical Holding AB and its competitors. Chordate Medical Holding AB's current Accounts Payable is kr1.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordate Medical Holding AB stock overvalued right now?
Chordate Medical Holding AB (OSTO:CMH) has a current Accounts Payable of kr1.40 Mil. The current Accounts Payable is kr1.40 Mil. Chordate Medical Holding AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Chordate Medical Holding AB (OSTO:CMH), the current Accounts Payable is kr1.40 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordate Medical Holding AB Business Description

Address Farogatan 33, 164 51 Kista, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel, and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.
46GF Score

Get the complete analysis for OSTO:CMH

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.16
Price